Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$30.91 USD
-0.14 (-0.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $30.90 -0.01 (-0.03%) 7:18 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Denali Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,035 | 1,336 | 865 | 1,470 | 415 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 30 | 36 | 32 | 26 | 15 |
Total Current Assets | 1,064 | 1,372 | 897 | 1,496 | 430 |
Net Property & Equipment | 46 | 44 | 39 | 41 | 47 |
Investments & Advances | 0 | 0 | 425 | 33 | 40 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 18 | 13 | 12 | 2 | 3 |
Total Assets | 1,154 | 1,460 | 1,404 | 1,604 | 553 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 3 | 5 | 1 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 69 | 67 | 53 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 294 | 320 | 71 | 43 |
Total Current Liabilities | 78 | 364 | 378 | 72 | 45 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 1 | 5 | 318 | 44 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 123 | 418 | 442 | 454 | 158 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 2 | 2 | 2 | 1 |
Capital Surplus | 2,145 | 2,019 | 1,608 | 1,504 | 819 |
Retained Earnings | -1,116 | -971 | -645 | -354 | -426 |
Other Equity | 1 | -7 | -3 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,031 | 1,042 | 962 | 1,151 | 395 |
Total Liabilities & Shareholder's Equity | 1,154 | 1,460 | 1,404 | 1,604 | 553 |
Total Common Equity | 1,031 | 1,042 | 962 | 1,151 | 395 |
Shares Outstanding | 138.80 | 135.80 | 122.10 | 119.90 | 96.00 |
Book Value Per Share | 7.43 | 7.68 | 7.88 | 9.60 | 4.11 |
Fiscal Year End for Denali Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 896 | 937 | 1,035 | 1,109 | 1,191 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 32 | 37 | 30 | 34 | 33 |
Total Current Assets | 928 | 974 | 1,064 | 1,143 | 1,224 |
Net Property & Equipment | 48 | 47 | 46 | 48 | 40 |
Investments & Advances | 451 | 491 | 0 | 8 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 51 | 45 | 18 | 11 | 14 |
Total Assets | 1,503 | 1,581 | 1,154 | 1,237 | 1,306 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 12 | 9 | 1 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 33 | 43 | 69 | 36 | 36 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 20 | 21 | 0 | 27 | 18 |
Total Current Liabilities | 75 | 83 | 78 | 71 | 69 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 116 | 126 | 123 | 118 | 119 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 2 | 2 | 2 | 2 |
Capital Surplus | 2,705 | 2,673 | 2,145 | 2,114 | 2,084 |
Retained Earnings | -1,317 | -1,218 | -1,116 | -997 | -897 |
Other Equity | -3 | -1 | 1 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,387 | 1,455 | 1,031 | 1,118 | 1,187 |
Total Liabilities & Shareholder's Equity | 1,503 | 1,581 | 1,154 | 1,237 | 1,306 |
Total Common Equity | 1,387 | 1,455 | 1,031 | 1,118 | 1,187 |
Shares Outstanding | 143.10 | 142.50 | 138.80 | 138.20 | 136.80 |
Book Value Per Share | 9.69 | 10.21 | 7.43 | 8.09 | 8.68 |